isotype control antibody murine igg1 control 13c4  (Genzyme)

Journal: Bone

Article Title: Early TGF-β inhibition in mice reduces the incidence of breast cancer induced bone disease in a myeloid dependent manner

doi: 10.1016/j.bone.2018.05.008

Figure Lengend Snippet: A. Experimental outline for 1D11 experiments, athymic (left), BALB/c (right). B. Experimental outline for WT/TGF-βRIIMyeKO mice. C. Representative athymic x-ray images of early, middle and late disease. D. Representative BALB/c x-ray images of early, middle and late disease. E. Representative x-ray images of early, middle and late disease for WT/TGF-βRIIMyeKO mice. F. Western blot analysis from naïve BALB/c mice treated with 13C4 or 1D11. Spleen lysate from a mouse treated with 1D11 demonstrates a decrease in p-Smad 2/3 levels.

Article Snippet: The TGF-β neutralizing antibody (1D11) and its isotype control (13C4) were generously provided by SANOFI.

Techniques: Western Blot

Journal: Bone

Article Title: Early TGF-β inhibition in mice reduces the incidence of breast cancer induced bone disease in a myeloid dependent manner

doi: 10.1016/j.bone.2018.05.008

Figure Lengend Snippet: X-ray analysis of tumor-bearing mice at late stage disease prior to sacrifice. Representative images are from late stage disease. Formalin fixed tibias were scanned and analyzed by μCT as described in the methods section. Percent bone volume normalized to total volume (BV/TV) for each treatment group. A. Athymic mouse model: X-ray images, 13C4 treated (left), 1D11 treated (right) and quantification of bone lesions. Tumor-bearing athymic mice treated with 1D11 have less osteolytic lesions than isotype control. B. Left: three-dimensional (3D) rendered μCT images from two tumor-bearing athymic mice at late stage disease, 13C4 treated (left), 1D11 treated (right). Right: percent BV/TV over the course of tumor-induced bone disease (TIBD) in the athymic mouse model. Treatment with 1D11 increases overall bone volume over the course of TIBD. C. BALB/c mouse model: X-ray images, 13C4 treated (left), 1D11 treated (right) and quantification of bone lesions. Tumor-bearing BALB/c mice treated with 1D11 have less osteolytic lesions than isotype control. D. Left: 3D rendered μCT images from two tumor-bearing BALB/c mice at late stage disease, 13C4 treated (left), 1D11 treated (right). Right: percent BV/TV over the course of tumor-induced bone disease in the BALB/c mouse model. Treatment with 1D11 increases overall bone volume over the course of TIBD. E. WT/TGF-βRIIMyeKO mice mouse model: X-ray images, WT tumor (left), TGF-βRIIMyeKO tumor (right) and quantification of bone erosions. Tumor-bearing TGF-βRIIMyeKO have a reduced incidence of bone lesions as compared to tumor-bearing WT mice. F. Left: 3D rendered μCT images from two tumor-bearinF-βRIIMyeKO (right). Right: percent BV/TV over the course of tumor-induced bone disease in the WT/TGF-βRIIMyeKO mice mouse model. Tumor-bearing TGF-βRIIMyeKO mice only have a significant decrease in their overall bone volume at early disease. (9-13 tibias per group).

Article Snippet: The TGF-β neutralizing antibody (1D11) and its isotype control (13C4) were generously provided by SANOFI.

Techniques:

Journal: Bone

Article Title: Early TGF-β inhibition in mice reduces the incidence of breast cancer induced bone disease in a myeloid dependent manner

doi: 10.1016/j.bone.2018.05.008

Figure Lengend Snippet: Tibal sections were stained with hematoxylin & eosin (H+E) for tumor burden analysis at late stage disease as described in the methods section. A&B. 4× magnification H+E sections from two tumor-bearing mice (athymic and BALB/c) at late stage disease, 13C4 treated (left), 1D11 treated (right) and quantification of percent tumor burden between treatment groups at late stage disease. Tumor-bearing mice (athymic and BALB/c) treated with 1D11 have a reduction in tumor burden as compared to isotype control. C. 4× magnification H+E sections from two tumor-bearing WT and TGF-βRIIMyeKO mice at late stage disease, WT (left), TGF-βRIIMyeKO (right) and quantification of percent tumor burden between mice at late stage disease. Tumor-bearing TGF-βRIIMyeKO mice have a reduction in tumor burden as compared to isotype control. T, Tumor. BM, Bone Marrow. Scale, 50 μm.

Article Snippet: The TGF-β neutralizing antibody (1D11) and its isotype control (13C4) were generously provided by SANOFI.

Techniques: Staining

Journal: Scientific Reports

Article Title: Predictive computational modeling to define effective treatment strategies for bone metastatic prostate cancer

doi: 10.1038/srep29384

Figure Lengend Snippet: ( a ) Representative in silico outputs from control (left panel) and TGFβi (right panel) treated simulations at day 100. ( b – d ) In silico predictions of TGFβ inhibition on cancer cell growth ( b ), and cancer cell proliferative/apoptotic rates (average number of proliferating/apoptotic cancer cells at 25 day intervals over a 250 day period, ( c , d ). ( e ) Bioluminescence measurement of PAIII growth under TGFβi (1D11, 10 μg/ml; n = 10) or control (13C4, 10 μg/ml; n = 8) conditions. ( f ) pSMAD2 and pAKT positivity (red) as a ratio of unphosphorylated protein. Scale bars, 25 μm. ( g ) The proliferative and apoptotic index in TGFβi and control tissue sections were measured using pHistone H3 and cleaved caspase-3 (c-Caspase-3) (red) respectively as a ratio to total cell number (DAPI; blue). Scale bars, 50 μm. Asterisks denote statistical significance (*p < 0.05; **p < 0.005).

Article Snippet: Pre-Treatment Studies: 6-week old male SCID Beige mice were injected intraperitoneally with either TGFβ inhibitor (1D11; 10 μg/ml; n = 10/group) or isotype control, 13C4 (10 μg/ml; n = 8/group), a kind gift from Scott Lonning and Patrick Finn at Genzyme.

Techniques: In Silico, Control, Inhibition

Journal: Scientific Reports

Article Title: Predictive computational modeling to define effective treatment strategies for bone metastatic prostate cancer

doi: 10.1038/srep29384

Figure Lengend Snippet: ( a ) Immunofluorescence of TGFβ, TβRII, and pSMAD2 (red) in human (cytokeratin-green) bone metastatic prostate cancer (n = 20). Dashed box represents area of magnification. Graphs represent intensity of pixels. Scale bars represent 100 μm. ( b , c ) Real time PCR analysis of TβRI and TβRII expression ( b ) and ELISA measurement of TGFβ concentration ( c ) in PAIII, C42B and PC3. ( d ) The effect of increasing concentrations of TGFβ inhibitor (TGFβi; 1D11 antibody) on SMAD reporter activity (RLU). ( e ) The effect of TGFβ inhibition (TGFβi; 1D11 10 μg/ml) on colony formation and size compared to control (Control-13C4, 10 μg/ml). Asterisks denote statistical significance (*p < 0.05; **p < 0.01).

Article Snippet: Pre-Treatment Studies: 6-week old male SCID Beige mice were injected intraperitoneally with either TGFβ inhibitor (1D11; 10 μg/ml; n = 10/group) or isotype control, 13C4 (10 μg/ml; n = 8/group), a kind gift from Scott Lonning and Patrick Finn at Genzyme.

Techniques: Immunofluorescence, Real-time Polymerase Chain Reaction, Expressing, Enzyme-linked Immunosorbent Assay, Concentration Assay, Activity Assay, Inhibition, Control

Journal: PLoS ONE

Article Title: Blocking TGF-β Signaling Pathway Preserves Mitochondrial Proteostasis and Reduces Early Activation of PDGFRβ+ Pericytes in Aristolochic Acid Induced Acute Kidney Injury in Wistar Male Rats

doi: 10.1371/journal.pone.0157288

Figure Lengend Snippet: ( a ) Tissue lysates from kidney cortex were immunoblotted for TGFRβII, VEGFR2, PDGFRβ and glyceraldehyd 3-phosphate dehydrogenase (GAPDH) expression. Bands intensities of TGFRβII protein in studied groups (n = 3 for controls; n = 5 for AA and AA+control Ab groups; and n = 4 for and AA+anti-TGFβ group) were quantified by densitometry. ( b ) The control group displayed a basal level TGFRβII expression, and AA intoxication negatively regulated this expression. Bands intensities of VEGFR2 protein in studied groups (n = 3 for controls; n = 5 for AA and AA+control Ab groups; and n = 3 for and AA+anti-TGFβ group) were quantified by densitometry. ( c ) AA highly increases VEGFR2 expression and anti-TGF Ab had a protective effect. Bands intensities of PDGFRβ protein in studied groups (n = 3 for controls; n = 5 for AA, AA+control Ab and AA+anti-TGFβ groups) were quantified by densitometry. ( d ) Anti-TGF Ab and 13C4 had a protective effect on AA induced increase in PDGFRβ protein expression. Results are presented as means ± SEM. One way ANOVA, *** P < .001, * P < .05 comparison of each group versus control group; followed by Holm Sidak test, ### P < .001, # P < .05 comparison between all groups.

Article Snippet: Mouse pan-anti-TGFβ Ab (1D11) and its isotype control Ab (13C4) were obtained from Genzyme Corporation (New York, USA).

Techniques: Expressing, Control, Comparison